While recent volatility has been disappointing, it may have created attractive entry points for some ASX 200 shares.
Two such shares are listed below. Here's why analysts see a lot of value in them at current levels:
CSL Limited (ASX: CSL)
The first ASX 200 share to look at is CSL. It is one of the world's leading biotherapeutics and vaccine companies.
CSL has a world class portfolio of products that are used around the world to treat immunodeficiencies, bleeding disorders, hereditary angioedema, Alpha 1 antitrypsin deficiency, and neurological disorders.
But management isn't resting on its laurels. It is investing ~US$1 billion a year (and growing) into research and development and is in the process of making a major acquisition. The latter will add treatments for iron deficiency, nephrology and cardio-renal through the acquisition of Vifor Pharma for $17 billion.
The team at Citi is positive on its growth outlook over the coming years. For example, this year the broker is forecasting a net profit of US$3,158 million. It expects this to then grow to US$4,689 million by FY 2024.
Citi currently has a buy rating and $340.00 price target on the company's shares. This compares to the latest CSL share price of $264.52.
REA Group Limited (ASX: REA)
Another ASX 200 share to look at is REA Group. It is best known as the digital advertising company that operates Australia's leading property website, realestate.com.au.
But there's more to REA than just the realestate.com.au website. It also owns and operates a number of complementary businesses in the Australian market and internationally. These include property listing websites and mortgage broking.
All in all, together with new revenue streams, its good cost control, and a strong housing market, REA appears well-placed for growth over the coming years.
Goldman Sachs is confident in its growth outlook. It is forecasting a net profit of $388 million in FY 2022, $445 million in FY 2023, and then ultimately $510 million in FY 2024.
In light of this, the broker has put a buy rating and $193.00 price target on REA's shares. This compares to the current REA share price of $146.83.
